SG3 Management’s Apellis Pharmaceuticals APLS Stock Holding History

SG3 Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50,000	Closed	-$2.26M	–	293
2022 Q2	$2.26M	Sell	50,000 -50,000	-50%	-$2.28M	0.27%	72
2022 Q1	$5.08M	Buy	+100,000	New	+$4.41M	0.14%	141
2021 Q4	–	Sell	-265,700	Closed	-$8.76M	–	1025
2021 Q3	$8.76M	Buy	265,700 +195,700	+280%	+$11M	0.27%	74
2021 Q2	$4.42M	Buy	70,000 +54,500	+352%	+$2.81M	0.16%	150
2021 Q1	$665K	Buy	+15,500	New	+$733K	0.02%	706
2020 Q4	–	Sell	-15,000	Closed	-$453K	–	1006
2020 Q3	$453K	Buy	+15,000	New	+$448K	0.02%	591

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG3 Management's APLS Position: Q1 2023 in Review

SG3 Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 22,000 shares — an estimated $1.14M sold.

SG3 Management first reported a position in APLS in Q2 2021 and held it in 5 quarters. The position peaked at $3.3M in Q3 2021. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

SG3 Management reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 22,000 Apellis Pharmaceuticals shares in Q1 2023, an estimated $1.14M.
SG3 Management first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 5 quarters.
SG3 Management's Apellis Pharmaceuticals position peaked at $3.3M in Q3 2021.
281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.